Horizon Discovery Group plc Director/PDMR Shareholding (8359Q)
02 December 2016 - 10:30PM
UK Regulatory
TIDMHZD
RNS Number : 8359Q
Horizon Discovery Group plc
02 December 2016
Horizon Discovery Group plc
Director/PDMR Shareholding
Cambridge, UK, 2 December 2016: Horizon Discovery Group plc
(LSE: HZD) ("Horizon" or the "Company"), the world leader in the
application of gene editing technologies, today announces that on 2
December 2016 Dr Susan Galbraith, a Non-Executive Director of the
Company, purchased a total of 40,000 ordinary shares of 1p each in
the Company at a price of 119.75 pence per share. Following this
purchase of shares Dr Galbraith is interested in a total of 40,000
ordinary shares of 1p each in the Company representing
approximately 0.04% of Horizon's issued share capital.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
1 Details of the person discharging managerial
responsibilities/person closely associated
---- ----------------------------------------------------------
a) Name Dr Susan Galbraith
---- ------------------------- -------------------------------
2 Reason for the notification
---- ----------------------------------------------------------
a) Position/status Non-Executive Director
---- ------------------------- -------------------------------
b) Initial Initial Notification
notification
/Amendment
---- ------------------------- -------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
---- ----------------------------------------------------------
a) Name Horizon Discovery Group plc
---- ------------------------- -------------------------------
b) Legal Entity N/A
Identifier
---- ------------------------- -------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
---- ----------------------------------------------------------
a) Description Ordinary shares of 1.0p each
of the financial
instrument,
type of
instrument GB00BK8FL363
Identification
code
---- ------------------------- -------------------------------
b) Nature of Purchase of shares
the transaction
---- ------------------------- -------------------------------
c) Currency GBP
---- ------------------------- -------------------------------
d) Price(s) Price(s) Volume(s)
and volume(s)
---- ------------------------- -------------- ---------------
119.75p 40,000
------------------------------ -------------- ---------------
e) Aggregated
information
- Aggregated
volume
- Price 40,000
- Aggregated 119.75p
total
GBP47,900
------------------------------ -------------------------------
f) Date of 2 December 2016
the transaction
---- ------------------------- -------------------------------
g) Place of London Stock Exchange, AIM
the transaction
---- ------------------------- -------------------------------
- ENDS -
For further information from Horizon Discovery Group plc, please
contact:
Horizon Discovery Group plc
Darrin Disley, Chief Executive Officer
Richard Vellacott, Chief Financial Officer
Chris Claxton, VP Investor Relations
Tel: +44 (0) 1223 655 580
Consilium Strategic Communications (Financial Media and Investor
Relations)
Mary-Jane Elliott / Susan Stuart / Matthew Neal / Melissa
Gardiner
Tel: +44 (0) 20 3709 5701
Email: horizon@consilium-comms.com
Numis Securities Limited (Joint Broker and NOMAD)
Michael Meade / Freddie Barnfield
Tel: +44 (0) 207 260 1000
RBC Capital Markets (Joint Broker)
Paul Tomasic / Marcus Jackson
Tel: +44 (0) 20 7653 4000
About Horizon Discovery Group plc www.horizondiscovery.com
Horizon Discovery Group plc (LSE: HZD) ("Horizon"), is a
world-leading gene editing company that designs and engineers
genetically-modified cells and then applies them in research and
clinical applications that advance human health.
Horizon's core capabilities are built around its proprietary
translational genomics platform, a highly precise and flexible
suite of gene editing tools (rAAV, ZFN and CRISPR) able to alter
almost any gene sequence in human or mammalian cell-lines.
Horizon offers over 23,000 catalogue products and related
research services, almost all of which are based on the generation
and application of cell and in vivo models that accurately
recapitulate the disease-causing genetic anomalies found in
diseases like cancer. Horizon's commercial offering has been
adopted by c. 1,600 unique research organisations in over 50
countries as well as in the Company's own R&D pipeline to
support a greater understanding of the genetic drivers of disease
and the development of molecular, cell and gene therapies that can
be prescribed on a personalised basis.
Horizon is headquartered in Cambridge, UK, and is listed on the
London Stock Exchange's AIM market under the ticker "HZD".
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHFLLFBQLFLFBD
(END) Dow Jones Newswires
December 02, 2016 06:30 ET (11:30 GMT)
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From Apr 2024 to May 2024
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From May 2023 to May 2024